Shipra Gandhi
Medical Oncology · Buffalo, NYNPI 1801154711
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,132 of the $26,223 with a category attached, or 65.3%. 12 manufacturers reported payments, led by AstraZeneca at 39.4% of the total. Reporting peaked in 2024 at $12,006 and has fallen 55.6% since, to $5,331 in 2025.
Across 34 payments — averaging $771.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Roche Diagnostics Corporation$6K
- Stemline Therapeutics Inc.$2K
- Novartis$2K
- Genentech USA, Inc.$2K
- Gilead$1K
- plus $2K from 6 others
Across 58 payments — averaging $35,452 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$1.2M
- Merck$845K
- E.r. Squibb & Sons, L.L.C.$9K
- Eli Lilly$2K
What the payments were for
- Consulting fees$17,13265%
- Speaking & faculty fees$6,37524%
- Grants$3501%
- Travel & lodging$1,3275%
- Food & beverage$1,0274%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $10,337 |
| Roche Diagnostics Corporation | 5 | $6,402 |
| Stemline Therapeutics Inc. | 2 | $2,192 |
| Novartis | 2 | $2,054 |
| Genentech USA, Inc. | 2 | $1,991 |
| Gilead | 2 | $1,312 |
| Immunomedics, Inc. | 1 | $1,300 |
| Caris MPI, Inc. | 1 | $233 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Puma Biotechnology, Inc. | 1 | $125 |
| Merck | 1 | $115 |
| Tersera Therapeutics LLC | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,223 in reported general payments places this provider in the 70th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.